These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 16275167)
1. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Morishita R Atheroscler Suppl; 2005 Dec; 6(4):41-6. PubMed ID: 16275167 [TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. Douglas JS; Weintraub WS; Holmes D Clin Cardiol; 2003 Oct; 26(10):451-4. PubMed ID: 14579914 [TBL] [Abstract][Full Text] [Related]
3. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320 [TBL] [Abstract][Full Text] [Related]
4. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Zhang Z; Foster JK; Kolm P; Jurkovitz CT; Parker KM; Murrah NV; Anderson GT; Douglas JS; Weintraub WS Am Heart J; 2006 Oct; 152(4):770-6. PubMed ID: 16996857 [TBL] [Abstract][Full Text] [Related]
5. Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial. Weintraub WS; Foster J; Culler SD; Becker ER; Parker K; Zhang Z; Kolm P; Douglas JS; J Invasive Cardiol; 2004 May; 16(5):257-9. PubMed ID: 15152132 [TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Jang JS; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Kim DK; Seol SH; Kim DI; Cho KI; Kim BH; Park YH; Je HG; Jeong YH; Kim WJ; Lee JY; Lee SW Cardiology; 2012; 122(3):133-43. PubMed ID: 22832424 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Kunishima T; Musha H; Eto F; Iwasaki T; Nagashima J; Masui Y; So T; Nakamura T; Oohama N; Murayama M Clin Ther; 1997; 19(5):1058-66. PubMed ID: 9385493 [TBL] [Abstract][Full Text] [Related]
8. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Lee SW; Chun KJ; Park SW; Kim HS; Kim YH; Yun SC; Kim WJ; Lee JY; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Jon S; Cho YH; Lee NH; Kim JH; Park SJ Am J Cardiol; 2010 Jan; 105(2):168-73. PubMed ID: 20102913 [TBL] [Abstract][Full Text] [Related]
10. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Geng DF; Liu M; Jin DM; Wu W; Deng J; Wang JF Cardiology; 2012; 122(3):148-57. PubMed ID: 22832561 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Aoki M; Morishita R; Hayashi S; Jo N; Matsumoto K; Nakamura T; Kaneda Y; Ogihara T Diabetologia; 2001 Aug; 44(8):1034-42. PubMed ID: 11484082 [TBL] [Abstract][Full Text] [Related]
13. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials). Lee SW; Lee JY; Ahn JM; Park DW; Han S; Park YK; Lee WS; Jang JY; Kwon CH; Park GM; Cho YR; Kim WJ; Kang SJ; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ Am J Cardiol; 2013 Dec; 112(11):1738-44. PubMed ID: 24063835 [TBL] [Abstract][Full Text] [Related]
14. Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. El-Beyrouty C; Spinler SA Ann Pharmacother; 2001 Sep; 35(9):1108-13. PubMed ID: 11573862 [TBL] [Abstract][Full Text] [Related]
15. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. Jennings DL; Kalus JS J Clin Pharmacol; 2010 Apr; 50(4):415-21. PubMed ID: 20081227 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Friedland SN; Eisenberg MJ; Shimony A Am J Cardiol; 2012 May; 109(10):1397-404. PubMed ID: 22381162 [TBL] [Abstract][Full Text] [Related]
17. The vascular effects of cilostazol. Weintraub WS Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):56B-60B. PubMed ID: 16498513 [TBL] [Abstract][Full Text] [Related]
18. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Kozuma K; Hara K; Yamasaki M; Morino Y; Ayabe S; Kuroda Y; Tanabe K; Ikari Y; Tamura T Am Heart J; 2001 Jan; 141(1):124-30. PubMed ID: 11136497 [TBL] [Abstract][Full Text] [Related]
19. [Drug-eluting stents do they make the difference? ]. Presbitero P; Asioli M Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625 [TBL] [Abstract][Full Text] [Related]
20. Comparison of cilostazol and clopidogrel after successful coronary stenting. Lee SW; Park SW; Hong MK; Lee CW; Kim YH; Park JH; Kang SJ; Han KH; Kim JJ; Park SJ Am J Cardiol; 2005 Apr; 95(7):859-62. PubMed ID: 15781016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]